PMI Invested over $12.5 Billion in Smoke-free Technology

PMI by 2FIRSTS.ai
Apr.18.2024
PMI Invested over $12.5 Billion in Smoke-free Technology
Smoking's major health impacts widely known, WHO data shows over billion smokers globally, push for smoke-free alternatives intensifies.

According to a report from El País on April 16th, it is widely known that smoking has significant impacts on health. Therefore, the best choice is to never start smoking or to quit as soon as possible. However, according to data from the World Health Organization (WHO), there are still over a billion smokers worldwide, and this number is not expected to significantly decrease in the near to medium term.

 

Around the world, various methods and strategies have been implemented to help people quit smoking and encourage them to break this habit. These strategies and policies primarily focus on prevention and cessation, aiming to prevent people from starting smoking, especially young individuals, or helping current smokers kick the habit.

 

In recent years, scientists have developed a smokeless alternative through technology, indicating that it is a better choice than continuing to smoke. These alternatives do not involve combustion, are smokeless, and generally contain the addictive substance nicotine. Evidence shows that compared to traditional cigarettes, this method significantly reduces health risks. When smoking cigarettes, tobacco is burned at high temperatures, producing smoke that contains over 6000 chemical substances, including around a hundred that are proven or potentially harmful. Therefore, eliminating the combustion process is the main goal in developing smoking alternatives.

 

Such alternatives include e-cigarettes (commonly referred to as e-liquid or vape), which do not contain tobacco and only have nicotine solution, as well as heat-not-burn tobacco devices that, although they contain tobacco, only heat it up instead of burning it, resulting in significantly reduced harmful chemicals released compared to burning tobacco.

 

In addition, Philip Morris International (PMI) has been dedicated to seeking non-combustible alternative products. They continue to invest in technology and collaborate with partners to drive the global goal of achieving a smoke-free future. Since 2008, PMI has invested approximately $12.5 billion in research and development of new technologies, establishing a scientific evidence base, product manufacturing, marketing, and continued innovation.

 

Therefore, it is possible to help eliminate the impact of smoking on public health. However, this is not something that can be achieved overnight or by one party alone, but it requires cooperation from other relevant parties such as public authorities, the medical community, and the scientific community. Only in this way will there be real changes that have an impact on public health. At the same time, accurate information based on scientific evidence must be provided to adult smokers so that they can make informed decisions.

 

The PMI company stated that "with the appropriate regulatory environment, societal dialogue, and public support, many countries are expected to achieve smoke-free status within 10 to 15 years".

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

 FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.
News
May.13
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai
FDA Wins Default Entry in Case Against E-Cigarette Distributor, to Seek Permanent Injunction
FDA Wins Default Entry in Case Against E-Cigarette Distributor, to Seek Permanent Injunction
The U.S. Food and Drug Administration (FDA) has made procedural progress in its lawsuit against North Carolina-based e-cigarette distributor Dream Distro LLC and its owner. A federal district judge granted the government’s request for entry of default after the defendants failed to respond to the complaint within 21 days of service. The government will next seek a default judgment, including a permanent injunction.
Apr.09 by 2FIRSTS.ai
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit heard oral arguments on Tuesday in a case brought by seven small vape-liquid companies challenging the Food and Drug Administration’s denial of marketing authorization for their flavored electronic nicotine products.
Apr.30 by 2FIRSTS.ai
ELFBAR Resolves Global Dispute Over "ELF" Trademark with VPR Brands LP
ELFBAR Resolves Global Dispute Over "ELF" Trademark with VPR Brands LP
ELFBAR announces global settlement with VPR Brands LP over "ELF" trademark dispute, covering major markets like US, Canada, UK.
Apr.01 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13